RASAGILINE MESYLATE (rasagiline mesylate) by Teva is selective, irreversible mao-b inhibitor indicated for the treatment of idiopathic parkinson's disease. Approved for parkinson's disease (pd), parkinson's disease (), parkinson's disease. First approved in 2019.
Drug data last refreshed 20h ago
selective, irreversible MAO-B inhibitor indicated for the treatment of idiopathic Parkinson's disease. The results of a clinical trial designed to examine the effects of AZILECT on blood pressure when it is administered with increasing doses of tyramine indicates the functional selectivity can be…
Worked on RASAGILINE MESYLATE at Teva? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Clinical Trial to Assess Efficacy, Safety, and Tolerability of Rasagiline Mesylate 1 mg in Patients With Multiple System Atrophy of the Parkinsonian Subtype (MSA-P)
Safety, Tolerability, and Effectiveness of Rasagiline Mesylate in Patients With Parkinson's Disease